Key takeaways for New Hampshire
- • Insulin resistance is not a labeled FDA indication for any GLP-1.
- • Improvements typically substantial (30-50% HOMA-IR reduction).
- • Treat via parent diagnosis (obesity, PCOS, T2D, prediabetes).
- • New Hampshire Medicaid coverage rules apply for Insulin Resistance patients in New Hampshire — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Insulin Resistance
There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
New Hampshire-specific context
New Hampshire has telehealth access concentrated in Manchester, Nashua, Concord metros, with additional reach to Derry and Dover. Dartmouth Hitchcock Health, Elliot Health System is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.dhhs.nh.gov.
New Hampshiretelehealth & pricing rules
- • New Hampshire permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • New Hampshire allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New Hampshire: ~$282/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.